Last update 28 Jan 2026

STM-434

Overview

Basic Info

Drug Type
Fc fusion protein
Synonyms
AMG 434, STM 434
Target
ACVR2B
Action
inhibitors
Mechanism
ACVR2B inhibitors(Activin receptor type-2B inhibitors)
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseUrogenital Diseases
Active Indication
Ovarian Cancer
Inactive Indication
Advanced Malignant Solid NeoplasmEndometrial CarcinomaFallopian Tube Carcinoma+ [1]
Originator Organization
Amgen, Inc.Amgen, Inc.
Active Organization
Amgen, Inc.Amgen, Inc.
Inactive Organization
Santa Maria Biotherapeutics, Inc.
License Organization
Amgen, Inc.Amgen, Inc.Atara Biotherapeutics, Inc.Atara Biotherapeutics, Inc.
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with STM-434
NCT02262455
/ CompletedPhase 1
An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
100 Clinical Results associated with STM-434
Login to view more data
100 Translational Medicine associated with STM-434
Login to view more data
100 Patents (Medical) associated with STM-434
Login to view more data
100 Deals associated with STM-434
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
United States
Santa Maria Biotherapeutics, Inc.
01 Oct 2014
Endometrial CarcinomaPhase 1
United States
Santa Maria Biotherapeutics, Inc.
01 Oct 2014
Fallopian Tube CarcinomaPhase 1
United States
Santa Maria Biotherapeutics, Inc.
01 Oct 2014
Granulosa Cell TumorPhase 1
United States
Santa Maria Biotherapeutics, Inc.
01 Oct 2014
Ovarian CancerPhase 1-
Amgen, Inc.Amgen, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02262455 (Pubmed | Clin Cancer Res)
Phase 1
Granulosa Cell Tumor of the Ovary | Advanced Malignant Solid Neoplasm
32
ndljedziss(nqhyohconh) = increase mjjvbzjmdl (wyhsdhjbhl )
View more
-
15 Sep 2019
NCT02262455 (ASCO2016)
Phase 1
Granulosa Cell Tumor of the Ovary | HR-positive/HER2-low Solid Tumors
22
gthfwuhhvh(scruacwxpg) = n = 6 kqyahzmdar (vovmzvxwhz )
View more
Positive
20 May 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free